References
Coca A, Bundy KW, Marston B, Huggins J, Looney RJ (2009) Macrophage activation syndrome: serologicals markers and treatment with anti thymocyte globulin. Clin Immunol 132:10–18. doi:10.1016/j.clim.2009.02.005
Ringol S, Weiss PF, Beukelman T, Dewitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Nigrovic PA, Robinson AB, Vehe RK, American College of Rheumatology (2013) 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arhtritis Rheum 65:2499–2512. doi:10.1002/art.38092
Ravelli A, Grom AA, Behrens EM, Cron EQ (2012) Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun 13:289–298. doi:10.1038/gene.2012.3
Mahlaoui N, Ouachèe-Chardin M, de Saint BasileG, Neven B, Picaerd C, Blanche S, Fischer A (2007) Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients. Pediatrics 120:622–628
Schulert GS, Grom AA (2014) Macrophage activation syndrome and cytokine directed therapies. Best Pract Res Clin Rheumatol 28:277–292. doi:10.1016/j.berh.2014.03.002
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ozturk, K., Ekinci, Z. Successful treatment of macrophage activation syndrome due to systemic onset juvenile idiopathic arthritis with antithymocyte globulin. Rheumatol Int 35, 1779–1780 (2015). https://doi.org/10.1007/s00296-015-3321-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-015-3321-2